Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: A new class of anti-HIV agents

被引：48

作者：

Hagihara, M

Kashiwase, H

Katsube, T

Kimura, T

Komai, T

Momota, K

Ohmine, T

Nishigaki, T

Kimura, S

Shimada, K

机构：

[1] Ube Ind Ltd, Pharmaceut Res Dept, Ube Lab, Ube, Yamaguchi 7550067, Japan

[2] Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[3] Sankyo Co Ltd, Med Chem Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[4] Univ Tokyo, Dept Med, Bunkyo Ku, Tokyo 1138655, Japan

[5] Tokyo Senbai Hosp, Minato Ku, Tokyo 1088329, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1999年 / 9卷 / 21期

关键词：

D O I：

10.1016/S0960-894X(99)00537-5

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Synthesis and anti-HIV activity of a series of novel arylpiperazinyl fluoroquinolones are reported. In the SAR study, the aryl substituents on the piperazine nitrogen were found to play an important role for the anti-HIV-1 activity. A few of the compounds exhibited potent anti-HIV activity: IC50 = 0.06 mu M in chronically infected cells. (C) 1999 Elsevier Science Ltd. All rights reserved.

引用

页码：3063 / 3068

页数：6

共 18 条

[1]

Albrecht R, 1977, Prog Drug Res, V21, P9

[2] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].

Autran, B ;

Carcelain, G ;

Li, TS ;

Blanc, C ;

Mathez, D ;

Tubiana, R ;

Katlama, C ;

Debre, P ;

Leibowitch, J .

SCIENCE, 1997, 277 (5322) :112-116

[3] Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives [J].

Baba, M ;

Okamoto, M ;

Makino, M ;

Kimura, Y ;

Ikeuchi, T ;

Sakaguchi, T ;

Okamoto, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1250-1255

[4] INVITRO ACTIVITY OF CIPROFLOXACIN, NORFLOXACIN AND NALIDIXIC-ACID [J].

BAUERNFEIND, A ;

PETERMULLER, C .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1983, 2 (02) :111-115

[5] Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy [J].

Brodt, HR ;

Kamps, BS ;

Gute, P ;

Knupp, B ;

Staszewski, S ;

Helm, EB .

AIDS, 1997, 11 (14) :1731-1738

[6] Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].

Egger, M ;

Hirschel, B ;

Francioli, P ;

Sudre, P ;

Wirz, M ;

Flepp, M ;

Rickenbach, M ;

Malinverni, R ;

Vernazza, P ;

Battegay, M ;

Bernasconi, E ;

Burgisser, P ;

Erb, P ;

Fierz, W ;

Grob, P ;

Gruninger, U ;

Jeannerod, L ;

Ledergerber, B ;

Luthy, R ;

Matter, L ;

Opravil, M ;

Paccaud, F ;

Perrin, L ;

Pichler, W ;

Piffaretti, GC ;

Rutschmann, O ;

Zanetti, G .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199

[7] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].

Finzi, D ;

Hermankova, M ;

Pierson, T ;

Carruth, LM ;

Buck, C ;

Chaisson, RE ;

Quinn, TC ;

Chadwick, K ;

Margolick, J ;

Brookmeyer, R ;

Gallant, J ;

Markowitz, M ;

Ho, DD ;

Richman, DD ;

Siliciano, RF .

SCIENCE, 1997, 278 (5341) :1295-1300

[8] Decline in deaths from AIDS due to new antiretrovirals [J].

Hogg, RS ;

OShaughnessy, MV ;

Gataric, N ;

Yip, B ;

Craib, K ;

Schechter, MT ;

Montaner, JSG .

LANCET, 1997, 349 (9061) :1294-1294

[9] A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication [J].

Kashiwase, H ;

Momota, K ;

Ohmine, T ;

Komai, T ;

Kimura, T ;

Katsube, T ;

Nishigaki, T ;

Kimura, S ;

Shimada, K ;

Furukawa, H .

CHEMOTHERAPY, 1999, 45 (01) :48-55

[10]

KIMURA T, Patent No. 0572259

← 1 2 →